Podium to Practice: EHA 2025 – Multiple Myeloma: FIRST-IN-HUMAN STUDY OF JNJ-5322, IN PATIENTS WITH RRMM

Podium to Practice: EHA 2025 – Multiple Myeloma: FIRST-IN-HUMAN STUDY OF JNJ-5322, IN PATIENTS WITH RRMM

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Irwin Sandhu

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

S100 – FIRST-IN-HUMAN STUDY OF JNJ-79635322 (JNJ-5322), A NOVEL, NEXT-GENERATION TRISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL PHASE 1 RESULTS

Studies/trials discussed:

S100 – FIRST-IN-HUMAN STUDY OF JNJ-79635322 (JNJ-5322), A NOVEL, NEXT-GENERATION TRISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL PHASE 1 RESULTS
Tagged